ArticleClinical rheumatology2026
Evidence for acetylcholinesterase as an early mediator in knee osteoarthritis: insights from synovial fluid analyses.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionAcetylcholinesterase (AChE), a vital component of cholinergic neurotransmission, exhibits various noncholinergic functions. To understand its functional role in degenerative conditions like knee osteoarthritis (KOA), the specific activity of AChE in the synovium of OA knees (grades I-IV) was estimated, and the values were correlated with disease severity.
methodsForty patients with KOA were recruited and categorized into four groups based on the Kellgren-Lawrence classification of KOA as grades I, II, III, and IV, with ten patients in each group. Patient demographic information, including sex, age, pain duration, and visual analog scale (VAS) score, were collected and analyzed, along with the specific activity of synovial fluid AChE.
resultsThe majority of patients with KOA were 41-85 years of age, with a mean age of 64 ± 8.5 years. The VAS score analysis indicated that as the disease progressed, the pain was significantly higher. The specific activity of AChE in grades I, II, III, and IV was found to be 0.66, 0.98, 0.57, and 0.41 mU/mg of protein, respectively. Among the four grades, grade II KOA showed a significant increase in the AChE activity when compared with other grades of KOA (p < 0.05), followed by grade I.
conclusionOur findings indicate that the increase in AChE activity in KOA grades I and II may facilitate localized inflammation and promote cartilage degeneration in early stages. Therefore, the enzymatic function of AChE can be considered a potential therapeutic target in KOA after validating the finding with larger cohort studies. Key Points • Synovial acetylcholinesterase (AChE) activity is elevated in the early stages of Knee Osteoarthritis (KOA). • Increased AChE activity in the early stages of KOA suggests its potential role as a mediator of active inflammation and cartilage degeneration. • AChE can be considered as a potential therapeutic target in the early stages of joint degenerative conditions like KOA.
Indexed as
Identifiers
41493685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.